Printer Friendly

RML ANNOUNCES CHANGE OF NAME TO IMUTEC CORPORATION

 RML ANNOUNCES CHANGE OF NAME TO IMUTEC CORPORATION
 TORONTO, Aug. 24 /PRNewswire/ -- At today's annual and special


meeting, shareholders of RML Medical Laboratories Inc. approved a change in the company's name to IMUTEC Corporation.
 IMUTEC is developing proprietary biologic response modifier technology for the treatment of cancer and other diseases.
 "IMUTEC better captures the essence of our company, given our work with the human immune system," said Richard A. Potts, president. "We also believe the new name is more memorable, and will be an important asset as we continue to progress toward commercialization."
 RML's VIRULIZIN(TM) is undergoing Phase II clinical trials on five types of cancer: pancreas, melanoma, kidney, stomach, and recurrent colon and rectum. The program, at prominent hospitals in Canada and Mexico, will be significantly expanded over the coming 18 to 24 months -- with the company intending to file investigational new drug applications later in the fall for clinical trials of VIRULIZIN(TM) in the United States and Europe.
 Also at the annual meeting, IMUTEC announced the appointment of Dr. Jamie de la Garza, principal investigator for the clinical trial program with VIRULIZIN(TM) in Mexico, as a member of the company's Medical Advisory Board. Dr. de la Garza is a professor of clinical oncology at the University of Mexico and both director of research and post graduate studies and president of the scientific committee of the Mexican National Cancer Institute.
 -0- 8/24/92
 /CONTACT: David W. Cooke, director of corporate development of RML Medical Laboratories, 416-724-1100/
 (RMLB.) CO: RML Medical Laboratories Inc. ST: Ontario IN: MTC SU:


PS -- NY063 -- 2650 08/24/92 14:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1992
Words:271
Previous Article:REPUBLIC BANCORP DECLARES COMMON STOCK CASH DIVIDEND AND STOCK DIVIDEND
Next Article:MICHAEL FOODS ADDRESSES PATENT CONFUSION
Topics:


Related Articles
RML TO PROPOSE CHANGE OF NAME AT AUGUST 24 ANNUAL MEETING
RML EXPANDS CANCER TREATMENT CLINICAL TRIALS
REITER APPOINTED RML DIRECTOR
RML FILES FINAL PROSPECTUS
IMUTEC CORPORATION PHASE II STUDY OF VIRULIZIN IN PATIENTS WITH PANCREATIC CANCER RELEASED
SCIENTIFIC DEVELOPMENTS ADD TO VIRULIZIN KNOWLEDGE BASE
IMUTEC REPORTS FIRST QUARTER RESULTS
IMUTEC CORPORATION REPORTS SECOND QUARTER RESULTS
DR. JULES E. HARRIS APPOINTED TO IMUTEC MEDICAL ADVISORY BOARD
IMUTEC FILES FINAL PROSPECTUS TSE CONDITIONALLY APPROVES IMUTEC COMMON SHARE LISTING

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters